EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies

Zhaozhao Chen, Yu Hu, Heng Mei iD

Advanced Science · 2023-12 · 10 (35)

DOI: 10.1002/advs.202303215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 31.10.2023. Verfasst von Zhaozhao Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei, 43…. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Technology innovation plan key research and development projects of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Furthermore, CAR technologies for cancer immunotherapy have expanded from CAR‐T to CAR‐natural killer cell (CAR‐NK), CAR‐cytokine‐induced killer cell (CAR‐CIK), and CAR‐macrophage (CAR‐MΦ) therapy. Nevertheless, the high cost and complex manufacturing processes of ex vivo generation of autologous CAR products have hampered broader application. There is an urgent need to develop an efficient and economical paradigm shift for exploring new sourcing strategies and engineering approaches toward generating CAR‐engineered immune cells to benefit cancer patients. Currently, researchers are actively investigating various strategies to optimize the preparation and sourcing of these potent immunotherapeutic agents. In this work, the latest research progress is summarized. Perspectives on the future of CAR‐engineered immune cell manufacturing are provided, and the engineering approaches, and diverse sources used for their development are focused upon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellReceptors, Chimeric AntigenHumansNeoplasm Recurrence, LocalKiller Cells, NaturalImmunotherapy, Adoptive

Stichwörter der Autor:innen

CAR engineeringcancer immunotherapycell sourcesgene deliveryin vivo generationsoff-the-shelfsynthetic biology

Substanzen

Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei, 430022, China.
  • Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.

ORCID-Profile: Heng Mei

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Technology innovation plan key research and development projects of Hubei Province
  • National Key Research and Development Program of China

Zitieren

APA

Chen, Z., Hu, Y., & Mei, H. (2023). Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies. Advanced Science, 10(35). https://doi.org/10.1002/advs.202303215

Vancouver

Chen Z, Hu Y, Mei H. Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies. Advanced Science. 2023;10(35). doi:10.1002/advs.202303215

BibTeX
@article{Chen2023,
  author = {Chen, Zhaozhao and Hu, Yu and Mei, Heng},
  title = {Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {35},
  doi = {10.1002/advs.202303215}
}
Kostenlos starten →